IFT22

Across TCGA pan-cancer cohorts, IFT22 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated IFT22 data layer compared with 24 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher IFT22 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated IFT22 expression acts as an unfavorable survival marker, although some lineages such as LUAD show a favorable association.

LSCC, UCEC, and HNSC are the cancer types where IFT22 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Quartile	II,III,IV	0.792	1.000	.001	33	view →
UCEC	OS	Median	III,IV	0.449	1.000	.010	14	view →
HNSC	DFS	Tertile	All	0.528	0.759	.011	13	view →
LUAD	OS	Median	All	0.982	0.939	.015	5	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

IFT22–LSCC (DFS)

Open the LSCC breakdown →